Baird Reiterates Buy Rating on LRMR, Sets $5 Price Target
Baird analyst Joel Beatty reiterates a buy rating on LRMR with a price target of $5, a 56.25% upside from the current price.
Key Points
- Baird analyst Joel Beatty maintained a buy rating on LRMR, setting a price target of $5 on June 30, 2026.
- Baird's $5 price target implies 56.25% upside from Larimar Therapeutics, Inc.'s ($LRMR) current $3.20 share price.
- Shares of LRMR traded near $3.20 on Tuesday, with insider buying activity reported in May 2026.
- Institutional investors like Deerfield Management and Millennium Management adjusted their LRMR holdings recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Baird analyst Joel Beatty reiterated a buy rating on LRMR, setting a price target of $5 on June 30, 2026. This move comes as the stock traded near $3.20 on Tuesday.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in LRMR
Several institutional investors have adjusted their positions in LRMR. Deerfield Management Company increased its holdings by 5 million shares, ending with 35,606,974 shares valued at about $160.2 million, a 16.3% increase. Blue Owl Capital Holdings LP added 296,317 shares, bringing its total to 7,120,007 shares worth approximately $32 million, a 4.3% rise. BlackRock, Inc. also grew its position by 70,597 shares to 3,752,200 shares, valued at around $16.9 million, marking a 1.9% increase. Conversely, Millennium Management LLC reduced its stake by 1,581,086 shares to 3,625,278 shares, a decrease of 30.4%.
Insider Buying and Selling at Larimar Therapeutics, Inc.
On May 19, 2026, several insiders, including Joseph Truitt, Jonathan Leff, Jeffrey Sherman, Frank Thomas, Thomas Edward Hamilton, and James Flynn, each purchased 55,150 shares of LRMR. These transactions were not part of a pre-planned Rule 10b5-1 trading plan.
Analysts Set New Price Targets
On June 30, 2026, Baird maintained its buy rating on LRMR with a price target of $5. Earlier, on May 27, 2026, JP Morgan initiated a buy rating with a $9 target. Wedbush has consistently maintained a buy rating, with targets ranging from $11 to $13 over recent months. Citigroup also maintained a buy rating with a $14 target in February 2026.
Bottom Line
Baird's reaffirmation of a buy rating with a $5 price target for LRMR highlights continued analyst confidence. Shares have seen institutional adjustments, with significant insider buying activity in May 2026. Investors should note that these analyst ratings and institutional activities provide insights into market sentiment but are backward-looking and not indicative of future performance.
Get Larimar Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LRMR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.